Caroline L. Ng, Ph.D.
Affiliations: | 2011 | Microbiology | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Area:
Microbiology Biology, Molecular BiologyGoogle:
"Caroline Ng"Parents
Sign in to add mentor| Domenico Tortorella | grad student | 2011 | Mount Sinai School of Medicine | |
| (Molecular analysis of ER-to-cytosol polypeptide dislocation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Imhoff RD, Rosenthal MR, Ashraf K, et al. (2023) Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy. Bioorganic & Medicinal Chemistry Letters. 94: 129458 |
| Rosenthal M, Ng C. (2023) Parasite proteostasis and artemisinin resistance. Research Square |
| Deni I, Stokes BH, Ward KE, et al. (2023) Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome. Cell Chemical Biology |
| Rosenthal MR, Ng CL. (2021) A Proteasome Mutation Sensitizes Cam3.II K13 Parasites to DHA and OZ439. Acs Infectious Diseases |
| Rosenthal MR, Ng CL. (2020) artemisinin resistance: the effect of heme, protein damage, and parasite cell stress response. Acs Infectious Diseases |
| Stokes BH, Yoo E, Murithi JM, et al. (2019) Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. Plos Pathogens. 15: e1007722 |
| White J, Dhingra S, Deng X, et al. (2018) Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the clinical candidate DSM265. Acs Infectious Diseases |
| Yoo E, Stokes BH, de Jong H, et al. (2018) Defining the determinants of specificity of Plasmodium proteasome inhibitors. Journal of the American Chemical Society |
| Llanos-Cuentas A, Casapia M, Chuquiyauri R, et al. (2018) Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. The Lancet. Infectious Diseases |
| Vanaerschot M, Lucantoni L, Li T, et al. (2017) Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity. Nature Microbiology |